A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Venanprubart (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Jul 2024 Status changed from completed to discontinued.
- 14 Feb 2024 This trial has bee discontinued in Poland ,according to European clinical trial database
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.